Loading cancer entity…
Loading cancer entity…
Clinical trials
10,628 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,642)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00006669 | Rituximab Followed by Combination Chemotherapy in Treating Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma | withdrawn | Phase 2 | 0 | Medstar Health Research InstituteOTHER | 1 | Oct 27, 2021 | clinicaltrials |
| NCT04464889 | HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation | withdrawn | Phase 1 | 0 | Medigene AGINDUSTRY | 1 | Oct 8, 2021 | clinicaltrials |
| NCT00900120 | Collecting and Storing Blood Samples From Patients With Cancer | withdrawn | — | 0 | University of Medicine and Dentistry of New JerseyOTHER | 0 | Sep 21, 2021 | clinicaltrials |
| NCT03563040 | Study of Photopheresis in the Treatment of Erythrodermic MF and SS(PROMPT) | withdrawn | Phase 2 | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Sep 8, 2021 | clinicaltrials |
| NCT04584307 | Phase II Study of Immunomaintenance Using POmalidomide With Elotuzumab afteR Second Autologous Transplant(Immuno-POWER) | withdrawn | Phase 2 | 0 | Natalie CallendarOTHER | 0 | Aug 23, 2021 | clinicaltrials |
| NCT01101581 | Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL | withdrawn | Phase 1 / Phase 2 | 0 | Gilead SciencesINDUSTRY | 1 | Aug 18, 2021 | clinicaltrials |
| NCT03873025 | A Study of CXD101 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma(PLACARD) | withdrawn | Phase 1 / Phase 2 | 0 | University College, LondonOTHER | 0 | Aug 17, 2021 | clinicaltrials |
| NCT04288765 | Carfilzomib, Daratumumab, Lenalidomide and Dexamethasone as First Line Treatment in Multiple Myeloma | withdrawn | Phase 3 | 0 | Grupo Cooperativo de Hemopatías MalignasOTHER | 1 | Jul 9, 2021 | clinicaltrials |
| NCT03602898 | Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation | withdrawn | Phase 2 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 30, 2021 | clinicaltrials |
| NCT03586024 | Pembrolizumab in Relapsed or Refractory Extranodal NK/T- Cell Lymphoma, Nasal Type and EBV-associated Diffuse Large B Cell Lymphomas | withdrawn | Phase 1 / Phase 2 | 0 | Abramson Cancer Center at Penn MedicineOTHER | 1 | May 7, 2021 | clinicaltrials |
| NCT02301494 | Effectiveness of Imiquimod Topical Cream in Early Stage Cutaneous T-cell Lymphoma(CTCL) | withdrawn | N/A | 0 | Rochester General HospitalOTHER | 0 | Apr 27, 2021 | clinicaltrials |
| NCT02605694 | Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO) | withdrawn | Phase 2 | 0 | SecuraBioINDUSTRY | 1 | Mar 17, 2021 | clinicaltrials |
| NCT01652261 | Very Early FDG-PET/CT-response Adapted Therapy for Advanced Hodgkin Lymphoma (H11)(H11) | withdrawn | Phase 3 | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Feb 15, 2021 | clinicaltrials |
| NCT04373083 | Anti-PD-1 Antibody Treatment With Cemiplimab and Radiotherapy in Early-stage Classical Hodgkin Lymphoma | withdrawn | Phase 2 | 0 | Regeneron PharmaceuticalsINDUSTRY | 0 | Jan 15, 2021 | clinicaltrials |
| NCT03719898 | Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma | withdrawn | Phase 2 | 0 | Fox Chase Cancer CenterOTHER | 1 | Jan 5, 2021 | clinicaltrials |
| NCT03739606 | Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer | withdrawn | Phase 2 | 0 | City of Hope Medical CenterOTHER | 0 | Dec 17, 2020 | clinicaltrials |
| NCT04621955 | Observational Study of Home Administration of Carfilzomib(KARE-2) | withdrawn | — | 0 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Nov 9, 2020 | clinicaltrials |
| NCT04094766 | Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R Acute B Lymphoblastic Leukemia | withdrawn | Phase 1 | 0 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 1 | Nov 5, 2020 | clinicaltrials |
| NCT04230330 | Nivolumab in Combination With GDP/ L-asparaginase in NK/ T-cell Lymphoma | withdrawn | Phase 1 | 0 | National Cancer Centre, SingaporeOTHER | 1 | Nov 5, 2020 | clinicaltrials |
| NCT04503538 | Telemedicine for Early Detection of Cytokine Release Syndrome and Neurotoxicity | withdrawn | N/A | 0 | Wake Forest University Health SciencesOTHER | 0 | Oct 23, 2020 | clinicaltrials |
| NCT00551239 | Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma | withdrawn | Phase 3 | 0 | CTI BioPharmaINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT03553914 | PLM60 for Peripheral T Cell Lymphoma (PTCL) | withdrawn | Phase 1 / Phase 2 | 0 | Conjupro Biotherapeutics, Inc.INDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT04293900 | Diet, Physical Activity and Body Composition Changes During R-CHOP(R-CHOP-OS) | withdrawn | — | 0 | George Washington UniversityOTHER | 1 | Oct 6, 2020 | clinicaltrials |
| NCT00577161 | Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL | withdrawn | Phase 3 | 0 | CTI BioPharmaINDUSTRY | 1 | Oct 5, 2020 | clinicaltrials |
| NCT02786485 | Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT | withdrawn | Phase 1 | 0 | Bellicum PharmaceuticalsINDUSTRY | 0 | Oct 5, 2020 | clinicaltrials |
| NCT03925428 | Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Sep 28, 2020 | clinicaltrials |
| NCT01460602 | Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | Louisiana State University Health Sciences Center ShreveportOTHER | 1 | Sep 1, 2020 | clinicaltrials |
| NCT04355039 | INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple Myeloma | withdrawn | Phase 1 | 0 | Medical College of WisconsinOTHER | 0 | Aug 19, 2020 | clinicaltrials |
| NCT04233697 | Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma | withdrawn | Phase 1 | 0 | Columbia UniversityOTHER | 0 | Aug 13, 2020 | clinicaltrials |
| NCT00004114 | Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Hematologic Cancer | withdrawn | Phase 1 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 0 | Jul 31, 2020 | clinicaltrials |
| NCT03506802 | TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma(NYSCT MM) | withdrawn | Phase 1 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 24, 2020 | clinicaltrials |
| NCT04439305 | Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X) | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Jul 20, 2020 | clinicaltrials |
| NCT03145870 | Prevalence of Asymptomatic Thrombosis in Multiple Myeloma | withdrawn | N/A | 0 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Jul 17, 2020 | clinicaltrials |
| NCT03983486 | Rationale for Cytogenetic Risk Stratification by Imaging Flow Cytometry in Multiple Myeloma(CIF-PM) | withdrawn | — | 0 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Jul 17, 2020 | clinicaltrials |
| NCT03003728 | 2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT) | withdrawn | Phase 2 | 0 | University of ArkansasOTHER | 1 | Jul 10, 2020 | clinicaltrials |
| NCT03617484 | Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma | withdrawn | Phase 2 | 0 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jun 22, 2020 | clinicaltrials |
| NCT03617224 | Pembrolizumab and Total Skin Electron Beam Radiotherapy in Mycosis Fungoides and Sézary Syndrome | withdrawn | Phase 1 | 0 | University of Texas Southwestern Medical CenterOTHER | 1 | Apr 22, 2020 | clinicaltrials |
| NCT03719560 | Early Systemic Central Nervous System Prophylaxis in Diffuse Large B-cell Lymphoma(BrUOG-377) | withdrawn | Phase 2 | 0 | Brown UniversityOTHER | 1 | Apr 13, 2020 | clinicaltrials |
| NCT04024384 | Daratumumab as Maintenance After Peripheral Blood Stem Cell Transplantation From HLA-identical or Haploidentical Family Donor in the Treatment of Refractory or Relapsed Multiple Myeloma: a Phase 2 Trial(DARALLO) | withdrawn | Phase 2 | 0 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Mar 27, 2020 | clinicaltrials |
| NCT03328936 | Study of Personalized Melphalan Dosing in the Setting of Autologous Transplant | withdrawn | Phase 2 | 0 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 21, 2020 | clinicaltrials |
| NCT04043845 | ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies | withdrawn | Phase 1 | 0 | Dana-Farber Cancer InstituteOTHER | 0 | Feb 5, 2020 | clinicaltrials |
| NCT02800889 | Dose-Escalation Study of Pixantrone Monotherapy in Pediatric Patients With Relapsed or Refractory Cancer | withdrawn | Phase 1 | 0 | CTI BioPharmaINDUSTRY | 1 | Jan 29, 2020 | clinicaltrials |
| NCT03579927 | CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 29, 2020 | clinicaltrials |
| NCT01789723 | Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn | withdrawn | Phase 1 | 0 | Acrotech Biopharma Inc.INDUSTRY | 0 | Jan 23, 2020 | clinicaltrials |
| NCT02274506 | Infusion of Allogeneic, 3rd Party CD19-specific T Cells | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jan 22, 2020 | clinicaltrials |
| NCT03608501 | A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation(IDEALL) | withdrawn | Phase 2 | 0 | TakedaINDUSTRY | 1 | Jan 14, 2020 | clinicaltrials |
| NCT00006451 | Bone Marrow Transplantation in Treating Patients With Leukemia | withdrawn | Phase 3 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jan 3, 2020 | clinicaltrials |
| NCT03742804 | Study Of Intratumoral G100 In Cutaneous T Cell Lymphoma | withdrawn | Phase 2 | 0 | Yale UniversityOTHER | 0 | Dec 18, 2019 | clinicaltrials |
| NCT01415765 | MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Dec 17, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Oct 27, 2021source: clinicaltrials